Juan Gonzalez Perez AIDS Healthcare Foundation

Slides:

Advertisements

Similar presentations

Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.

Advertisements

PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.

Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.

Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

Decentralization of HIV care and treatment services in Central Province, Kenya: Adult patient characteristics and outcomes Presenting author: William Reidy,

ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Management and Development for Health (MDH)

Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.

Journal Club “Implementing a Tenofovir-Base First-Line Regimen in Rural Lesotho: Clinical Outcomes and Toxicities After Two Years” JAIDS 2011 Bygrave et.

Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.

Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.

Efficacy of routine viral load, CD4 cell count, and clinical monitoring of adults taking antiretroviral therapy in Rural Uganda Alex Coutinho MD MPH DTM&H.

MISSING DATA IN THE INFECTIOUS DISEASES INSTITUTE CLINIC DATABASE Agnes N Kiragga East Africa IeDEA investigators’ meeting 4-5 th May 2010 East African.

COST-EFFECTIVENESS OF THE WORLD HEALTH ORGANIZATION TREATMENT GUIDELINES IN AFRICA Eran Bendavid Philip Grant, Annie Talbot, Douglas Owens, Andrew Zolopa.

Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.

Outcomes in ART treatment programmes with and without access to routine viral load monitoring Olivia Keiser on behalf of IeDEA Southern Africa

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.

1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.

Retention in an antiretroviral program in the Democratic Republic of Congo Kalenga Lucien Koole Olivier Menten Joris Kiumbu Modeste Robin Ryder Mukumbi.

Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,

Early survival and clinic retention among high risk HIV-infected patients initiating cART in a pilot Express Care system compared to Routine Care in Western.

Carolinas Medical Center, Charlotte, NC Website:

Novel Antiretroviral Studies and Strategies

Switch to PI/r monotherapy

Associate Professor, Honorary Consultant Cardiologist

Factors associated with loss to follow up in a primary healthcare clinic practicing test and treat Authors: Julius Kiwanuka1,2, Noah Kiwanuka3, Flavia.

I have no conflicts of interest to declare

Justine Mirembe MD, MPH ICASA, 5th December 2011

Earlier treatment and lower mortality in infants Initiating ART at

The Ethiopian TB HAART study: Find out the timing for ART when CD4< 200cells/µL Anything new? Wondwossen Amogne, Abiy H/ wold, Getent Yimer,

Anastasiia Raievska (Veramed)

Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital

Factors affecting virological failure in patients receiving antiretroviral therapy: a prospective HIV Clinical cohort in rural Uganda. Patrick Kazooba1,

14th European AIDS Conference

L.F. Jefferys1, J. Hector1, M.A. Hobbins2, J. Ehmer2, N. Anderegg3

First roll out of universal access to antiretroviral therapy under routine program conditions in rural Swaziland. Authors: Bernhard Kerschberger (1), Sikhathele.

Community ART delivery models for high patient’s retention and good

Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda

Clinical outcome after SVR: Veterans Affairs

1University of Maryland; 2Futures Group International; 3CDC; 4USAID

Statistics 103 Monday, July 10, 2017.

11/23/2018 National University of Lesotho, Southern Africa

Dr. Velephi Okello, Principal Investigator, MaxART Trial

Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2

Extended ART Initiation Criteria Can Be Implemented Successfully in Rural South Africa Sarah Jane Steele1, Gemma Arellano2, Tom Ellman3, Amir Shroufi1,

DIRECÇÃO PROVINCIAL DE SAÚDE TETE

Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017

Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,

24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.

Clinical outcome after SVR: ANRS CO22 HEPATHER

Towards the last 90% of the 90:90:90 strategy: A review of viral suppression rates in a HIV program in Central and Eastern Kenya Dr Moses Kitheka,

Management and Development for Health (MDH)

Comparison of NNRTI vs PI/r

Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

Incidence of HCC after HCV treatment with DAAs: ERCHIVES

ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.

Dr. Grace Namayanja – Kaye 24 July 2019

Public Health Implications

Presentation transcript:

Juan Gonzalez Perez AIDS Healthcare Foundation Is AZT-3TC-NVP still the best choice? Clinical outcomes of antiretroviral therapy in a Ugandan cohort Juan Gonzalez Perez AIDS Healthcare Foundation

Background Studies have found that TDF-containing regimens associated with less drug substitution and better tolerance compared with AZT regimens. Results on mortality and retention are conflicting, with some observational studies suggesting that AZT-3TC-NVP could be associated with better outcomes (Chi 2011, Eguzo 2014)

Objectives Estimate 12 months attrition by regimen in a cohort of patients initiated on ART in 4 sites in Uganda Compare clinical outcomes in the first year on ART between the four first line regimens recommended by WHO

Methods Retrospective observational cohort study. Exposure= ARV regimen during the 1st year of treatment. Outcome: 12 months attrition (LTFU+ death) Site: 4 facilities supported by AHF in Uganda: 2 Kampala/ 2 Central Region. Duration of the study: August 2005 until November 2014

Methods Study population: Adults (15 and above) started on AZT or TDF- containing 1st line regimens with complete demographic, baseline and follow up clinical data including: Age, gender, Baseline weight, WHO stage and CD4, ART start date, regimens and history TB treat 1st year ART

Statistical analysis Descriptive analysis: Patient characteristics at ART initiation by regimen compared using chi-squared or Kruskal-Wallis testing. Analytical techniques used: Kaplan-Meier survival methods to determine time to attrition Cox proportional hazards model to adjust for potential confounders Robust SE Propensity scores to account for non-randomized regimen allocation

Study Sites (Uganda)

Results

Cohort description 11,795 adults starting TDF or AZT containing regimens 7,017 excluded because: 6,365 missing baseline data 652 incomplete information on ART regimens first year 5,430 meet eligibility criteria for analysis cohort 1,061 (20%) start AZT-3TC-NVP 3,066 (56%) Start TDF-3TC-EFV 980 (18%) Start TDF-3TC-NVP 323 (6%) Start AZT-3TC-EFV

Population description Total (n=5,430) AGE: median (IQR) 32 (27-39) SEX Male: % 41% WEIGHT: median (IQR) 56 (50-63) WHO STAGE 3-4: % 22% CD4: median (IQR) 273 (143-382) YEAR of initiation 2011 or before 2012-2013 2014 415 (8%) 3112 (57%) 1903 (35%) TB treatment 1st year ART 293 (5%) Health facility: Site 1 Site 2 Site 3 Site 4 2,051 (38%) 916 (17%) 1570 (29%) 893 (16%) Outcomes LTFU Death Total attrition 851 133 984 (18%)

Population description AZT/3TC/NVP (n=1,061) TDF/3TC/EFV (n=3,066) TDF/3TC/NVP (n=980) AZT/3TC/EFV (n=323) p-value AGE: median (IQR) 33 (29-41) 31 (26-38) 33 (28-41) 35 (28-41) <0.001 SEX Male: % 47% 38% 46% 45% WEIGHT: median (IQR) 56 (50-62) 57 (50-64) 55 (49-62) 57(51-64) WHO STAGE 3-4: % 27% 19% 25% 29% CD4: median (IQR) 197 (110-281) 327 (195-436) 198 (113-295) 312 (177-414) YEAR of initiation 2011 or before 2012-2013 2014 246 (23%) 680 (64%) 135 (13%) 39 (1%) 1483 (48%) 1545 (51%) 84 (9%) 750 (77%) 146 (15%) 47 (15%) 199 (61%) 77 (24%) TB treatment 1st year ART 23 (2%) 191 (7%) 18 (2%) 51 (16%) Health facility: Site 1 Site 2 Site 3 Site 4 245 (23%) 106 (10%) 515 (49%) 195 (18%) 1,123 (37%) 653 (21%) 725 (24%) 565 (18%) 603 (61%) 107 (11%) 189 (19%) 81 (8%) 80 (25%) 50 (15%) 141 (44%) 52 (16%) Outcomes LTFU Death Total attrition 157 27 184 (17%) 483 57 540 (18%) 161 41 202 (20%) 50 8 58 (17%) 0.003

Population description AZT/3TC/NVP (n=1,061) TDF/3TC/EFV (n=3,066) TDF/3TC/NVP (n=980) AZT/3TC/EFV (n=323) p-value AGE: median (IQR) 33 (29-41) 31 (26-38) 33 (28-41) 35 (28-41) <0.001 SEX Male: % 47% 38% 46% 45% WEIGHT: median (IQR) 56 (50-62) 57 (50-64) 55 (49-62) 57(51-64) WHO STAGE 3-4: % 27% 19% 25% 29% CD4: median (IQR) 197 (110-281) 327 (195-436) 198 (113-295) 312 (177-414) YEAR of initiation 2011 or before 2012-2013 2014 246 (23%) 680 (64%) 135 (13%) 39 (1%) 1483 (48%) 1545 (51%) 84 (9%) 750 (77%) 146 (15%) 47 (15%) 199 (61%) 77 (24%) TB treatment 1st year ART 23 (2%) 191 (7%) 18 (2%) 51 (16%) Health facility: Site 1 Site 2 Site 3 Site 4 245 (23%) 106 (10%) 515 (49%) 195 (18%) 1,123 (37%) 653 (21%) 725 (24%) 565 (18%) 603 (61%) 107 (11%) 189 (19%) 81 (8%) 80 (25%) 50 (15%) 141 (44%) 52 (16%) Outcomes LTFU Death Total attrition 157 27 184 (17%) 483 57 540 (18%) 161 41 202 (20%) 50 8 58 (17%) 0.003

Kaplan-Meier analysis 12 months Attrition AZT/3TC/NVP 18% AZT/3TC/EFV 19% TDF/3TC/EFV 21% TDF/3TC/NVP 22% Log rank p-value= 0.09

Multivariable analysis: Cox model aHR (95% CI) p-value ART regimen AZT/3TC/NVP Ref TDF/3TC/EFV 1.48 (1.23-1.69) <0.001 TDF/3TC/NVP 1.26 (1.03-1.54) 0.02 AZT/3TC/EFV 1.22 (0.91-1.65) 0.17 Sex (male) 1.19 (1.03-1.37) 0.01 Age (10 year increase) 0.90 (0.83-0.97) WHO Stage 3-4 1.29 (1.10-1.52) 0.002 Weight 0.97 (0.96-0.98) < 0.001 CD4 baseline cells/uL < 100 100-200 0.64 (0.53-0.8) > 200 0.57 (0.43-0.74) Year ART initiation 2011 or before 2012-2013 1.37 (1.90-2.10) 0.13 2014 0.87 (0.45-1.67) 0.68 TB treatment 1st year 0.91 (0.68-1.22) 0.65

Conclusion In the data from our cohort AZT-3TC-NVP was associated with better retention at 12 months when compared with TDF-containing regimens Inferiority of TDF+3TC+NVP has been suggested in comparative studies before. For TDF+3TC+EFV, we hypothesized that in contexts like the one in our study, with limited access to investigations and reduced capacity to rule out OI, the increased potency of TDF+3TC+EFV to suppress viral replication (and cause more severe IRIS in those with undetected OIs) could be one factor to explain its negative performance

Acknowledgements Buzaalirwa Lydia Ssamula Kate Ikapule Jonathan Ssali John Lubanga Augustine Ssemakadde Matthew Babakhani Arin Iutung Amor Penninah Agnes Kiragga

Thank you

Observational studies comparing 1st line regimens SSA Bygrave 2011: 1124 patients started in TDF, d4T or AZT regimens in 2008 in Lesotho No difference between groups in terms of mortality and LTFU Chi 2011: 18,866 patients starting ARV in Lusaka 2007-2010, looking at the association between ARV regimen (initial, at time of event, predominant exposure) and outcomes Results of AZT-3TC-NVP were better than TDF regimens when categorizing drug regimen at time of event on Mortality and Program failure (30d lag time)

Observational studies comparing 1st line regimens SSA Velen 2014: 6169 patients started in TDF, d4T or AZT regimens between 2007 and 2009 from 2 different programs (workplace and community) in SA Sensitivity analysis in the community program didn’t find differences in mortality and LTFU between TDF and AZT regimens Eguzo 2014: 1069 patients started 2008-2013 in Nigeria In Cox model mortality of patients started on TDF regimens was higher (HR 1.88, p=0.03) compared with patients initiated on AZT/3TC regimens